Reply

Affiliations

¹ Massachusetts General Hospital, Boston, MA.
² Boston University School of Medicine, Boston, MA.
³ University of Otago, Christchurch, New Zealand.
⁴ University of Auckland, Auckland, New Zealand.
⁵ VA San Diego Healthcare System and University of California San Diego, La Jolla, CA.

Comment

Hyon Choi et al. Arthritis Rheumatol. 2019 Mar.

. 2019 Mar;71(3):481-482.

doi: 10.1002/art.40742. Epub 2019 Feb 7.

¹ Massachusetts General Hospital, Boston, MA.
² Boston University School of Medicine, Boston, MA.
³ University of Otago, Christchurch, New Zealand.
⁴ University of Auckland, Auckland, New Zealand.
⁵ VA San Diego Healthcare System and University of California San Diego, La Jolla, CA.

No abstract available

Comment on

New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. Choi H, et al. Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583. Arthritis Rheumatol. 2018. PMID: 29869840 Free PMC article.
Fresh Perspectives on the CARES Trial and the Use of Febuxostat in an Asian Population: Comment on the Article by Choi et al.
Wu X, Li C. Wu X, et al. Arthritis Rheumatol. 2019 Mar;71(3):479-481. doi: 10.1002/art.40741. Arthritis Rheumatol. 2019. PMID: 30294926 No abstract available.
Febuxostat Does Not Increase All-Cause Mortality and Cardiovascular Mortality Compared With Placebo: Comment on the Article by Choi et al.
Kuwabara M. Kuwabara M. Arthritis Rheumatol. 2019 Mar;71(3):479. doi: 10.1002/art.40744. Arthritis Rheumatol. 2019. PMID: 30295433 No abstract available.